Author: News Room
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Snowflake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Snowflake between June 27, 2023 and February 28, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Snowflake Inc. (“Snowflake” or the “Company”) (NYSE:…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Richtech To Contact Him Directly To Discuss Their Options If you purchased or acquiring securities in Richtech between January 27, 2026 and 12:00 PM ET on January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against…
Las Vegas, NV, Feb. 26, 2026 (GLOBE NEWSWIRE) — ACT Expo, The Leading Fleet Technology Show, today announced that John Smith, incoming president & CEO of FedEx Freight, will deliver the opening keynote at ACT Expo 2026, taking place May 4-7 at the Las Vegas Convention Center. His keynote will kick off four days where the entire commercial transportation ecosystem gathers to evaluate the technologies, strategies, and investments shaping fleet performance in the years ahead. In his leadership role at FedEx Freight, Smith oversees North America’s largest less-than-truckload (LTL) freight network, a division that generated $8.9 billion in revenue in…
NEW YORK and LONDON and BARCELONA, Spain, Feb. 26, 2026 (GLOBE NEWSWIRE) — Questex’s Fierce Network TV (FNTV) today released its 2026 Networked Agentic AI Index, a comparative assessment of how major telecom and cloud vendors are deploying networked agentic AI inside live carrier environments. The report, AI Agents of Change, authored by Stephen M. Saunders MBE, concludes that the future of telecom AI will be decided not by who has the biggest models — but by who controls orchestration. Ericsson tops the index (15/15), followed closely by Nokia (14/15), reflecting strong carrier trust, bounded autonomy models, and conservative placement…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). Faruqi…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In agilon health To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in agilon health between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against agilon health, inc. (“agilon” or…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. (“Picard” or…
Not for release to US wire service or distribution in the United States PERTH, Western Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to provide an update on the status of the capital raising announced on 24 February 2026 (Vancouver)/25 February 2026 (Perth). The Company has now received firm commitments to raise gross proceeds of C$7.9m (approximately A$8.2m) through a placement of ~16.8m units at C$0.10 per unit and ~61.1m Chess Depository Interests (“CDIs”) at A$0.105 per CDI to institutional, professional and sophisticated investors (“Placement”). The…
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Sciometrix Inc. (“Sciometrix”), a privately held healthcare technology and value-based care solutions provider headquartered in Michigan and developer of the Clinicus digital care management platform, that would, if consummated, result in Tevogen holding a majority voting interest in Sciometrix. The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise.…